404 related articles for article (PubMed ID: 27786552)
1. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
[TBL] [Abstract][Full Text] [Related]
2. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
5. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
8. Anti-Alzheimer drugs: life-threatening adverse effects.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
[TBL] [Abstract][Full Text] [Related]
9. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic management of Alzheimer disease.
Downey D
J Neurosci Nurs; 2008 Feb; 40(1):55-9. PubMed ID: 18330411
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of Alzheimer's disease].
Johannsen P
Ugeskr Laeger; 2006 Oct; 168(40):3424-9. PubMed ID: 17032609
[TBL] [Abstract][Full Text] [Related]
13. Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Pai MC; Aref H; Bassil N; Kandiah N; Lee JH; Srinivasan AV; diTommaso S; Yuksel O
Clin Interv Aging; 2015; 10():1779-87. PubMed ID: 26622172
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
15. Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
Thornton SL; Pchelnikova JL; Cantrell FL
J Pediatr; 2016 May; 172():147-50. PubMed ID: 26935787
[TBL] [Abstract][Full Text] [Related]
16. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
17. Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Isik AT; Bozoglu E; Yay A; Soysal P; Ateskan U
Am J Alzheimers Dis Other Demen; 2012 May; 27(3):171-4. PubMed ID: 22573283
[TBL] [Abstract][Full Text] [Related]
18. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
20. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Ehret MJ; Chamberlin KW
Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
